Imagion Biosystems Limited announced the NewPhase Ltd., an Israeli biotechnology company developing cancer treatments, has placed an order totaling approximately $300k for the supply of Imagion’s proprietary nanoparticles for 2020 to be used in the NewPhase product.
Read the announcement.
Imagion Biosystems’ IND Application for MagSense® Phase 2 Clinical Trial Clears FDA Review
June 3, 2026
Imagion Biosystems, Ltd. (ASX: IBX) has announced that the US Food and Drug Administration (FDA) completed its review of the company’s investigational new drug (IND)